87233-61-2

Basic information

• Product Name: Emedastine
• Synonyms: EMEDASTINE;1-(2-Ethoxyethyl)-2-(4-methyl-1,4-diazepan-1-yl)benzimidazole;1-(2-Ethoxyethyl)-2-(4-methylhexahydro-1H-1,4-diazepine-1-yl)-1H-benzimidazole;1-(2-Ethoxyethyl)-2-[(hexahydro-4-methyl-1H-1,4-diazepin)-1-yl]-1H-benzimidazole;1-(2-ethoxyethyl)-2-(4-Methyl-1,4-diazepan-1-yl)-1H-1,3-benzodiazole;1-(2-Ethoxyethyl)-2-(4-methyl-1,4-diazepan-1-yl)-1H-benzimidazole;1-(2-ethoxyethyl)-2-(4-methyl-1,4-diazepan-1-yl)-1H-benzo[d]imidazole
• CAS NO: 87233-61-2
• Molecular Formula: C₁₇H₂₆N₄O
• Molecular Weight: 302.41
• EINECS: 200-258-5
• Product Categories: impurity
• Mol File: 87233-61-2.mol
• Article Data: 4

Chemical Properties

• Boiling Point: 446.6 °C at 760 mmHg
• Flash Point: 223.9 °C
• Appearance: /
• Density: 1.15 g/cm³
• Vapor Pressure: 3.59E-08mmHg at 25°C
• Refractive Index: 1.594
• Storage Temp.: 2-8°C
• PKA: 8.86±0.10(Predicted)
• CAS DataBase Reference: Emedastine(CAS DataBase Reference)
• NIST Chemistry Reference: Emedastine(87233-61-2)
• EPA Substance Registry System: Emedastine(87233-61-2)

Safety Data

• Hazardous Substances Data: 87233-61-2(Hazardous Substances Data)

Usage

Uses

Antihistaminic, H1-receptor; asthma prophylactic; anti-allergic.

Definition

ChEBI: 1-Methyl-1,4-diazepane in which the hydrogen attached to the nitrogen at position 4 is substituted by a 1-(2-ethoxyethyl)-1H-benzimidazol-2-yl group. A relatively selective histamine H1 antagonist, it is used as the ifumatate salt for allergic rhinitis, urticaria, and pruritic skin disorders, and in eyedrops for the symptomatic relief of allergic conjuntivitis.

Brand name

Emadine (Alcon).

Clinical Use

Emedastine also is a newer antihistamine used topically in the eye for conjunctivitis. It has very high H1 receptor selectivity characteristics, and it is structurally related to the benzimidazoles, such as astemizole. Inhibition of mast cell release of inflammatory mediators has been noted.

InChI:InChI=1/C17H26N4O/c1-3-22-14-13-21-16-8-5-4-7-15(16)18-17(21)20-10-6-9-19(2)11-12-20/h4-5,7-8H,3,6,9-14H2,1-2H3

Upstream product

• 4318-37-0 1-Methylhomopiperazine 
• 87233-54-3 1-(2-ethoxyethyl)-2-chloro-1H-benzimidazole 

Relevant articles and documents

Preparation method of emedastine compound

The invention provides a preparation method of an emedastine compound, and belongs to the technical field of preparation of drug intermediates. According to the method, 2-hydroxy-1-ethoxyethyl-1-H-benzimidazole (a compound with a structure as shown in a formula 1) is taken as a starting material and is directly subjected to substitution reaction with N-methylhomopiperazine under the action of a catalyst and an alkali reagent, reactions of amide chlorination in an existing method and N-methylhomopiperazine substitution are combined into one step, and emedastine is directly obtained. High-toxicity reagents such as phosphorus oxychloride and phosphorus trichloride are not needed. The preparation method disclosed by the invention is simple to operate and few in reaction steps, toxic and harmful reagents are prevented from being used, the used reagents are low in price, the production cost is greatly reduced, and the product purity is larger than 99%; the target product is stable in quality and has a good industrial application prospect; and the method disclosed by the invention is mild in reaction condition, simple in post-treatment and suitable for industrial production.

SUBSTITUTED N-METHYL-N-(4-(4-(1H-BENZIMIDAZOL-2-YL) {1,4}DIAZEPAN-1-YL)-2-(ARYL)BUTYL) BENZAMIDES USEFUL FOR THE TREATMENT OF ALLERGIC DISEASES

The present invention relates to novel N-methyl-N-(4-(4-(1H-benzimidazol-2-yl)[1,4]diazepan-1-yl)-2-(aryl)butyl)benzamide derivatives of the formula: STR1 stereoisomers thereof, and pharmaceutically acceptable salts thereof which are useful as histamine receptor antagonists and tachykinin receptor antagonists. Such antagonists are useful in the treatment of allergic rhinitis, including seasonal rhinitis and sinusitis; inflammatory bowel diseases, including Crohn's disease and ulcerative colitis; asthma; bronchitis; and emesis.